DDI, drug-drug interaction; IVIVE, in vitro-in vivo extrapolation; PBPK, physiologically based pharmacokinetic; PK, pharmacokinetic.
 15 
on behalf of the International Transporter Consortium
Drug transporters can govern the absorption, distribution, metabolism, and excretion of substrate drugs and endogenous substances. Investigations to examine their potential impact to pharmacokinetic (PK) drug-drug interactions (DDIs) are an integral part of the risk assessment in drug development. To evaluate a new molecular entity as a potential perpetrator of transporters, use of well characterized and/or clinically relevant probe substrates with good selectivity and sensitivity are critical for robust clinical DDI assessment that could inform DDI management strategy in the product labeling. The availability of endogenous biomarkers to monitor transportermediated DDIs in early phases of clinical investigations would greatly benefit downstream clinical plans. This article reviews the state-of-the-art in transporter clinical probe drugs and emerging biomarkers, including current challenges and limitations, delineates methods and workflows to identify and validate novel endogenous biomarkers to support clinical DDI evaluations, and proposes how these probe drugs or biomarkers could be used in drug development.
Drug transporters can modulate the absorption, distribution, metabolism, and excretion (ADME) of substrate drugs and endogenous substances, ultimately determining their exposure in systemic circulation and tissues. 1 Transporter substrate or modulator (inhibitor or inducer) drugs can become clinical victims or perpetrators of drug-drug interactions (DDIs), respectively, when the transporter in question is a substantial contributor to the pharmacokinetics (PK) of the victim drug and can be inhibited or induced in the clinical setting. For example, lapatinib, a P-glycoprotein (P-gp) inhibitor, increased digoxin exposure by 2.8-fold (TYKERB labeling at Drugs@FDA), whereas tipranavir/ ritonavir, a P-gp inducer, decreased saquinavir/ritonavir exposure by 76% (APTIVUS labeling at Drugs@FDA). Understanding DDIs is an integral part of risk assessment in drug development considering the common practice of concomitant use of multiple medications. [1] [2] [3] STATE of the ART Previous International Transporter Consortium (ITC) whitepapers and regulatory guidelines have proposed an integrated approach (in vitro, in vivo, and in silico) to assess DDI potential and to inform safe drug use. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Multiple factors contribute to the decision on whether a clinical DDI study may be necessary, and, if so, its prioritization during drug development and subsequent interpretation of clinical DDI data to inform the product labeling. From the perspective of a new molecular entity (NME) as a transporter inhibitor, prediction of clinical DDI potential involves comparison of in vitro transporter inhibitory potency to various transporters that govern the victim drug's intestinal, liver portal, systemic, and tissue exposure. In this regard, in vitro transporter inhibition assays have been routinely used to determine whether an NME is an inhibitor of clinically relevant transporters, which serve as a trigger for follow-up clinical DDI studies. 4, 5 However, this approach may result in falsepositive or false-negative predictions due to the limitations of in vitro transporter assays and/or gaps in in vitro to in vivo extrapolation (IVIVE). [6] [7] [8] For instance, the assumptions are often made that the transporter-mediated pathway accounts for 100% of drug elimination, however, the contribution of transporter(s) to overall elimination of drugs is often not known or cannot be accurately measured.
Endogenous substances can exhibit transporter-mediated disposition, and their concentrations may be altered when transporter activity is modulated. [9] [10] [11] These endogenous substances have the potential to serve as biomarkers to study transporter function in vivo in humans. Transporter biomarkers offer the potential for evaluating NMEs as transporter inhibitors in early clinical studies, and with appropriate validation, may obviate the need for dedicated clinical DDI studies. For the purposes of drug development planning, it would be invaluable to corroborate or refute inhibition of transporters predicted from in vitro data using biomarkers, particularly in situations where in vitro prediction methods have high false-positive rates. For clinical DDI studies evaluating an NME as an inhibitor, use of selective and sensitive probe substrate drugs is a key to determine clinical risk for transporter inhibition, provide a mechanistic insight, extrapolate the results to other unstudied drugs, and inform the drug labeling to provide recommendations based on the DDI results. However, this has been challenging by the multiplicity of transporter substrates and inhibitors, the presence of multiple drug binding sites in many drug transporters, and complex interplay with drug metabolizing enzymes. 5, [12] [13] [14] Therefore, probe drugs currently used for clinical DDI studies are largely based on the likelihood of co-administration, without comprehensive understanding and evaluation of their ADME properties/in vitro transporter profiles, which limits extrapolation of the results to other drugs. Validated clinical probes are critical for robust clinical DDI assessment that ultimately drives product labeling to inform concomitant drug use. Table 1 outlines key features of an ideal probe drug or a biomarker, which can be used in vivo to assess transporter perpetrator DDIs. Notably, very few such probe substrate drugs or biomarkers have been identified to date.
This article reviews the state-of-the-art of transporter clinical probe drugs and emerging biomarkers, provides recommendations on use of relevant transporter probe substrates for DDI evaluation, and some potential transporter endogenous biomarkers for further characterization and validation, as well as current challenges and limitations. Furthermore, the article practically delineates methods and workflows to identify and validate novel endogenous biomarkers to support clinical DDI evaluation, and proposes their potential utility and application in drug development.
STATE-OF-THE-ART IN CLINICAL PROBE DRUGS AND POTENTIAL ENDOGENOUS BIOMARKERS FOR CLINICAL TRANSPORTER DDI ASSESSMENT
Clinical DDI assessment for an NME as a transporter inhibitor is typically conducted by administering an accepted probe substrate with the NME. In this section, we have conducted a critical and comprehensive analysis of probe substrate drugs commonly used for the transporters recommended by the ITC and regulatory agencies for clinical DDI evaluation based on their ADME properties, in vitro transporter profiles, and in vitro and clinical DDI data. 1, 4, 5, [12] [13] [14] Figure 1 illustrates recommended probe substrate drugs with a relatively high selectivity (based on relative contribution of transporter-mediated pathways to overall elimination of drugs) and sensitivity (based on clinical DDI studies with known potent transporter inhibitors and/or pharmacogenomic studies in subjects carrying nonfunction or reduced-function alleles) 15, 16 with detailed ADME properties, in vitro transporter profile, and examples of clinical DDIs summarized in Table 2 . These probe substrate drugs in general meet the following criteria:
• In vitro transporter profiles are relatively well characterized, and show higher transport activity and selectivity for the transporter of interest. • Clinical data show significant contribution of the transporter of interest in the overall elimination as indicated by o the ratio of area under the plasma concentration-time profile (AUCR) ≥ 2 o and/or the ratio of plasma clearance (CL) (or renal clearance (CLr) for renal transporters) CLR or CLr R ≤ 0.5
Either in the presence of a potent transporter inhibitor or in subjects with reduced function caused by a transporter polymorphism. , and fexofenadine are probe drugs for multidrug resistance 1 protein P-glycoprotein (P-gp, ABCB1), and sulfasalazine and rosuvastatin for breast cancer resistance protein (BCRP, ABCG2). Pitavastatin, atorvastatin, and rosuvastatin are probe drugs for the organic anion transporting polypeptides (OATP1B1 SLCO1B1) and OATP1B3 (SLCO1B3); coproporphyrin I (CPI) and CPIII, glycochenodeoxycholate-3-O-sulfate (GCDCA-S), conjugated and unconjugated bilirubin (CB and UCB) are potential endogenous biomarkers for OATP1B1 and OATP1B3. Hexadecanedioate (HDA) and tetradecanedioate (TDA) are potential biomarkers for OATP1B1. Sumatriptan is a probe drug for organic cation transporter 1 (OCT1, SLC22A1). Metformin is a probe drug for organic cation transporter 2 (OCT2, SLC22A2) and multidrug and toxin extrusion protein MATE1 (SLC47A1) and MATE2K (SLC47A2); N1-methylnicotinamide (NMN) and creatinine are potential endogenous biomarkers of OCT2/MATE1/2K. Adefovir is a probe drug for organic anion transporter 1 (OAT1, SLC22A6); taurine is a potential endogenous biomarker for OAT1. Benzylpenicillin is a probe drug of organic anion transporter 3 (OAT3; SLC22A8); 6β-hydroxycortisol (6βHC) and GCDCA-S are potential endogenous biomarkers of OAT3. a Potential endogenous biomarkers with relatively higher selectivity and/or sensitivity for clinical evaluation based on current literature data. b Substrates of OATP1B1, but not OATP1B3. Green colored circles: uptake transporters; and purple colored circles: efflux transporters. • Are commercially available and have relatively rich clinical DDI data.
STATE of the ART
In this section, potential utility and limitations of probe substrate drugs summarized in Figure 1 are discussed, together with recent examples of clinical probe drug cocktails used to simultaneously explore DDIs involving multiple drug transporters and metabolizing enzymes. [17] [18] [19] [20] Several endogenous substrates have been identified as potential endogenous biomarkers to evaluate inhibition of major hepatic and renal transporters in humans. [9] [10] [11] The endogenous substrates with initial clinical DDI evaluation are highlighted in Figure 1 . Recent progresses in identifying and evaluating these potential biomarkers are discussed below and some key preclinical and clinical data are summarized in Table 3 and Table S1 .
Liver transporters: organic anion transporting polypeptide 1B1/1B3 and organic cation transporter 1
Organic anion transporting polypeptide 1B1/1B3
• Probe drugs
Pitavastatin, rosuvastatin, and atorvastatin are widely used as clinical probe drugs for the evaluation of organic anion transporting polypeptide 1B1/1B3 (OATP1B)-mediated DDIs, either following a clinically relevant oral dose or a microdose as part of a drug cocktail [18] [19] [20] [21] [22] (Figure 1 and Table 2 ). Although considered as OATP1B substrates, the aforementioned drugs as well as other proposed "probes" have been shown to be substrates for other transporters in vitro, such as OATP2B1, sodium-taurocholate cotransporting polypeptide (NTCP), breast cancer resistance protein (BCRP), P-gp, organic anion transporter 3 (OAT3), and multidrug resistance-associated protein 4 (MRP4) and MRP3. 21, 23, 24 Pitavastatin is considered as the most sensitive OATP1B1 probe, 22 supported by > 80% fraction transported via OATP1B1, which has been estimated from in vitro, human ADME, SLCO1B1 (OATP1B1) c.521T>C pharmacogenomic data, and DDI data with i.v. vs. orally administered rifampin, a potent inhibitor for OATP1B. Pharmacogenomic data highlight similar sensitivity to SCLO1B1 for simvastatin acid, 15, 16, 25 but its complex PK (lactoneacid interconversion) and OATP1B-cytochrome P450 (CYP)3A interplay may limit its general use as a selective OATP1B clinical probe. In the case of rosuvastatin, the alteration of the activity of multiple non-OATP1B transporters expressed in the intestine (BCRP and OATP2B1), liver (NTCP and OATP2B1), or kidneys (OAT3) may be the driver behind the observed change in its PK following the oral administration of an inhibitor that can affect these transporters. Like rosuvastatin, atorvastatin presents a suitable OATP1B1 probe drug because of supporting pharmacogenomics data, 26 clinical DDI data with rifampin and mechanistic insight regarding OATP1B as the rate-determining step driving its hepatic disposition. 27 Nonetheless, the potential effect of inhibiting intestinal CYP3A4 and BCRP/P-gp efflux should also be considered when interpreting the observed changes in its systemic exposure. STATE of the ART To date, the endogenous substrates of OATP1B include coproporphyrins (CPs), bile acids (BAs), sulfated and glucuronidated BAs, fatty acid dicarboxylates, bilirubin, glucuronidated bilirubin, thyroid hormones and their metabolites, steroids, and sulfated and glucuronidated steroids. Among them, CPI, CPIII, glycochenodeoxycholate-3-O-sulfate (GCDCA-S), hexadecanedioate (HDA), tetradecanedioate (TDA), conjugated and unconjugated bilirubin (CB and UCB) present as potential biomarkers for clinical evaluation of OATP1B-mediated DDIs, but each has limitations [9] [10] [11] (Figure 1 and Table 3 ). In most cases, evidence for their utility as OATP1B biomarkers is based on animal data and careful profiling of plasma and urine of human SLCO1B genotyped subjects. For example, patients with Rotor syndrome lack expression of OATP1B1 and OATP1B3 are characterized by increased urinary excretion of CPI and higher bilirubin in the blood due to reduced uptake into the liver. 28 Likewise, pharmacogenomic studies indicate that individuals genotyped SLCO1B1*15 and SLCO1B1 c.521T>C show increased exposure of UCB, CB, and some BAs. [29] [30] [31] Compelling clinical evidence supporting HDA, TDA, GCDCA-S, and bilirubin as potential endogenous biomarkers for OATP1B1 has come from metabolomic and genomewide association studies (GWAS), which show a significant association of SLCO1B1 c.521T>C with the plasma levels of these endogenous substances. [32] [33] [34] The clinical data are consistent with the results obtained in Oatp1a/1b −/− mice, as they exhibit higher plasma CPI, CPIII, UCB, CB, and BA concentrations 28, 35, 36 ( Table S1 ). In addition, in vitro studies using transportertransfected cells and hepatocytes with an OATP1B inhibitor (e.g., rifampin) confirm that CPI, CPIII, GCDCA-S, HDA, TDA, CB, and UCB are substrates for OATP1B1 ( Table 3) . These biomarkers are also substrates for OATP1B3, with the exception of HDA and TDA. In addition, they are also transported by other hepatic and renal transporters, such as MRP2 and MRP3 (CPI, CPIII, and CB), OATP2B1 (CPIII), OAT1 (HDA and TDA), OAT3 (GCDCA-S, HDA, and TDA), and NTCP (GCDCA-S; Table 3 ), which may limit their selectivity.
Concerns regarding transporter selectivity aside, the abovementioned endogenous biomarkers are capable of recapitulating some clinical OATP1B DDIs. For example, a single oral dose of rifampin (600 mg) has been shown to markedly increase the area under the curve (AUC) of GCDCA-S (10-20-fold). 37 This increase was significantly greater than the changes in plasma simeprevir, bosentan, and repaglinide exposures in the same study (7.2-fold, 3.2-fold, and 1.9-fold, respectively). 34 Results of recent studies have also shown that changes in CPI plasma exposure correlate with presumably different levels of OATP1B inhibition imposed by OATP1B inhibitors that showed different in vivo inhibition (e.g., simeprevir, JNJ-A, and GDC-0810) with known OATP1B substrates. 38, 40 To date, however, reported OATP1B clinical DDI studies with concomitant monitoring of both clinical probe drugs and endogenous biomarker(s) are still limited in number [37] [38] [39] [40] [41] (Table 3) .
In summary, CPI, CPIII, GCDCA-S, HDA, TDA, CB, and UCB have demonstrated initial promise as clinical OATP1B biomarkers, in which CPI seems to be the most promising biomarker with higher selectivity and sensitivity. Further characterization and validation is needed to determine their predictive value for OATP1B-related DDIs. Until other confounding factors, including overlapping substrate selectivity for transporters and enzymes, disease, diet, and circadian rhythm, are fully understood, a single OATP1B biomarker may not be sufficient for effective overall evaluation of OATP1B inhibition risk and the use of multiple biomarkers may be warranted.
Organic cation transporter 1
Metformin is a well-known substrate of organic cation transporter 1 (OCT1). It is also a substrate for OCT2 and multidrug and toxin extrusion (MATE)1 and MATE2K transporters. Metformin may not be a suitable clinical OCT1 probe drug if only changes in PK are monitored, 42 because OCT1 modulation does not impact metformin systemic PK, and it only impacts metformin hepatic distribution and pharmacodynamic (PD) response. 42, 43 Currently, OCT1 probe substrate drugs have only been validated clinically in pharmacogenetic studies by comparing individuals expressing inactive or reduced function of OCT1 vs. wildtype controls. 15, 42, 44 Clinical OCT1 probes identified to date include sumatriptan, 45 ondansetron, and tropisetron. 46 Overall, sumatriptan and tropisetron are promising probe substrates of OCT1 because they exhibit a 2.2-fold and 4.9-fold increase in AUC, respectively, in subjects with a polymorphism resulting in reduced OCT1 activity vs. controls. 45, 46 Of the two, sumatriptan is most promising as a drug probe for OCT1 because evidence is available from a prospective study in healthy subjects 45 (Table 2) . Additional DDI studies with OCT1 inhibitors are warranted to better characterize their clinical utility as probe drugs for OCT1.
Fenoterol is also a promising clinical OCT1 probe with both notable systemic PK and PD effects of OCT1 modulation, but it is practically problematic, because it is not approved in the United States. 47 The O-desmethyl metabolite of tramadol 48, 49 is a sensitive OCT1 probe with both notable PK and PD effects during OCT1 modulation. However, metabolites are generally not preferred probes in the drug development setting due to additional data interpretation complexity associated with metabolite formation that may be influenced by NME and population variability (e.g., pharmacogenetic factors). Morphine 50 may be a useful OCT1 probe, but clinical studies conducted to-date were inconsistent, and morphine cannot presently be recommended as an OCT1 probe until these findings are clarified (e.g., oral administration of the prodrug vs. parenteral administration of morphine directly). Besides OCT1, morphine is a substrate for UDP-glucuronosyltransferase (UGT) and P-gp. Moreover, morphine is a controlled substance and DDI studies with controlled substances are not practical (or safe).
• Endogenous substrates (potential biomarker)
Thiamine is a substrate of OCT1 51 (Table S1) , however, clinical evidence supporting thiamine as an endogenous OCT1 probe is lacking. Preclinical studies using Oct1 −/− mice showed that the concentrations of thiamine and its metabolites in the knockout mouse liver following i.v. administration were reduced by > 50% compared to wild-type animals, whereas plasma levels were increased 30-40%, confirming the role of Oct1 in thiamine hepatic disposition in vivo. However, thiamine is not selective for OCT1 because it is also a substrate for OCT2, MATE1, MATE2K, and thiamine transporter 1 and 2 (THTR1 and THTR2). 52, 53 Notably, up to 9% of white people exhibit an OCT1 deficient phenotype, which has not been associated with markedly elevated systemic thiamine concentrations, possibly due to variability associated with dietary intake. This may make thiamine an impractical clinical OCT1 biomarker.
Recently, acylcarnitines, intermediate metabolites of mitochondrial oxidation, was identified as endogenous substrates of OCT1 through GWAS, targeted metabolomics, transporter transfected cells, and Oct1 liver specific knockout mice. 54 These studies have illustrated the role of OCT1 in the efflux of acylcarnitines from the liver to the circulation. Additional clinical DDI studies, however, are needed to assess the suitability of acylcarnitine as a potential endogenous biomarker of OCT1. It is worth noting that the GWAS showed that serum acylcarnitine levels are also significantly associated with organic cation/carnitine transporter 1 (OCTN1; SLC22A4), UGT1A1, and carnitine palmitoyltransferase 1 genes 55 and acylcarnitine is also an in vitro substrate of OCTN2, which may limit the selectivity of acylcarnitine as a biomarker for OCT1. 55 Kidney transporters: OAT1/3, OCT2, and MATE1/2K
Organic anion transporter 1 and 3
• Probe drugs
Despite overlapping substrate specificity between OAT1 and OAT3, adefovir is a relatively selective OAT1 probe, because its transport by OAT3 is minimal 56 (Figure 1 , Table 2 ). Adefovir is also transported by the apically localized renal efflux transporter MRP4. 57 However, plasma and renal clearance of adefovir was only slightly decreased in Mrp4 −/− mice, suggesting that change in Mrp4 activity may not have significant impact on its plasma exposure. 57 Probenecid, a potent inhibitor of OATs, caused a 2.1fold increase in adefovir plasma AUC ( Table 2 ), suggesting that adefovir may be used as a probe drug for OAT1. In contrast, benzylpenicillin (also named as penicillin G) ( Figure 1, Table 2 ) is a more selective OAT3 substrate. 56, 58 Probenecid increased plasma AUC of benzylpenicillin by 3.3-fold 56 ( Table 2 ), suggesting that it may serve as an OAT3 probe substrate. As discussed in the drug probe cocktail section below, furosemide, a dual substrate of OAT1 and OAT3, could be a useful probe to study the inhibition to both OAT1 and OAT3. 17 
• Endogenous substrates (potential biomarker)
Taurine is an endogenous OAT1 substrate, whereas 6βhydroxycortisol (6βHC) and GCDCA-S are substrates of OAT3; they may, therefore, potentially serve as endogenous biomarkers for assessing DDIs with these transporters 9, 10 (Figure 1, Table 3 ). In a clinical study, probenecid exhibited dose-dependent reduction of CL r of taurine and GCDCA-S without altering their plasma AUC, possibly due to inhibition of additional transporters at the apical side of renal tubule cells by probenecid (e.g., OAT4 and MRP2). However, the CL r values for both compounds correlated strongly with benzylpenicillin (an OAT3 probe drug) and 6βHC, suggesting that either compound may serve as a biomarker for OAT1 or OAT3 by monitoring their CLr. 59 Unlike 6βHC, the CL r of taurine and GCDCA-S was below glomerular filtration rate (GFR), indicating potential reabsorption from the urine in addition to tubular secretion. The selectivity of GCDCA-S as an endogenous OAT3 probe is limited because probenecid can inhibit apically localized OAT4 and MRP2, which may be involved in the reabsorption and urinary excretion of GCDCA-S, respectively. Additionally, GCDCA-S is also known as an endogenous substrate of hepatic OATP1B 60 ( Table 3 ) and as such, may confound its selectivity for OAT3. The 6βHC is formed by hepatic CYP3A4 and excreted into urine. It is also known as a biomarker for induction of CYP3A4 and any change in CYP3A4 activity may, therefore, influence the sensitivity and selectivity of 6βHC as an OAT3 biomarker. 61 Besides OAT3, 6βHC is a substrate for MATE1 and MATE2K. 62 Probenecid significantly increased plasma AUC, but reduced CL r of 6βHC, whereas pyrimethamine (a MATEs inhibitor) did not change systemic 6βHC AUC or CL r significantly. 62 Neither probenecid nor pyrimethamine affected CYP3A4 and 11β-hydroxysteroid dehydrogenase 2 activity responsible for the formation of 6βHC and conversion of 6βHC to 6β-hydroxycortisone, respectively. 62 Recently, pyridoxic acid and homovanillic acid have been identified as endogenous substrates of OAT1/3 using metabolomic analysis and DDI studies in cynomolgus monkeys. 63 Additional studies are needed to validate their potential utility as OAT1/3 biomarkers in humans.
Organic cation transporter 2 and multi drug and toxin extrusion 1 and 2K transporters

• Probe drugs
Metformin is a well-known and broadly used probe drug to study inhibition of the renal uptake transporter OCT2, and efflux transporters MATE1/2K. 64 For example, MATE1/2K inhibitor pyrimethamine significantly changed metformin plasma AUC and CL r by the inhibition of its active renal secretion 65, 66 (Figure 1 , Table 2 ). However, distribution of metformin to the liver, its primary site of action, but not clearance, is mediated by OCT1. 67 Recent studies suggest that metformin is also a substrate of OCT3, which is key to its skeletal muscle distribution (another site of action). The absorption and distribution of metformin is a complex and poorly understood process that involves at least several transporters, including THTR-2 and OCT1/3. 64 Lack of selectivity of most transporter inhibitors further complicates the interpretation of metformin renal DDI data. For instance, famotidine (a selective MATE1 inhibitor) at a high dose (200-800 mg/day) resulted in an increase, rather than the expected decrease in metformin CL r . 68 Famotidine co-administration also caused a transient enhancement of the antihyperglycemic effects of metformin, likely due to enhanced hepatic distribution through MATE1 inhibition. 68 Due STATE of the ART to the unique complexity of metformin mechanistic disposition, a separate commentary in this issue of CPT is dedicated to clinical DDI study design consideration for metformin. 43 • Endogenous substrates (potential biomarker) N1-methylnicotinamide (NMN) is an endogenous substrate of OCT2, and MATE1/2K. 69 Pyrimethamine almost completely inhibited its CL r via active secretion without altering its plasma exposure. 69 Trimethoprim, another OCT2/MATEs inhibitor, also reduced NMN CL r , which correlated with the change in metformin exposure in the same healthy subjects. 70 Recent studies reported increased NMN CL r in pregnant women, which was positively correlated with an increase in metformin CL r . 71 These clinical observations suggest the potential use of NMN as an endogenous biomarker for DDIs involving OCT2/MATEs (Figure 1 , Table 3 ). However, it is worth noting that renal elimination of NMN also involves active tubular reabsorption. 72 Creatinine is commonly used as a biomarker for renal function. Increased serum creatinine and reduced creatinine CL r could be a result of transient inhibition of renal transporters involved in its active secretion (OCT2, OAT2, and MATE1/2K), without altering GFR 73 (Figure 1 , Table 3 ). However, creatinine levels are influenced by many factors, such as weight, gender, age, muscle metabolism, and diet. A retrospective analysis of the change of creatinine level and DDI data with OCT2/MATEs inhibition suggests that creatinine is not a sensitive biomarker for OCT2/ MATEs inhibition, despite the fact that elevation of serum creatinine is frequently associated with inhibition of OCT2/MATEs. 73 Therefore, incorporation of creatinine with other biomarkers, such as NMN, may be needed to evaluate the risk for OCT2/MATEs inhibition.
Gut transporters: P-gp and BCRP P-glycoprotein
Digoxin, dabigatran etexilate (DE), and fexofenadine are recommended by regulatory agencies as clinical probe drugs for P-gp inhibition (Figure 1 , Table 2 ). However, there are a number of limitations regarding the suitability of digoxin as a P-gp probe, including the involvement of additional transporters and/or the low sensitivity of the DDI signal largely due to high oral bioavailability (60-80%). Despite these limitations, clinical DDIs with digoxin have been most extensively evaluated because digoxin exhibits a narrow therapeutic index and is commonly used in the clinical setting. The impact of NMEs on digoxin PK should, therefore, be carefully monitored as a safety precaution. 74 However, DDI data obtained with digoxin cannot be readily extrapolated to other P-gp substrate drugs. 75 The limitation of fexofenadine as a P-gp probe is the involvement of OATPs (OATP2B1 and OATP1B1/1B3) and OAT3 in its absorption, hepatic, and renal elimination. 76, 77 Fexofenadine, therefore, can be selected as a P-gp probe only when OATPs/OAT3 inhibition is not involved in the DDIs. DE, a prodrug of dabigatran, is a P-gp substrate, whereas its active moiety dabigatran is not. 78 Thus, DE could be a more selective P-gp probe to study P-gp inhibition in the gut, as P-gp-mediated efflux is restricted to limiting intestinal absorption of DE. However, PK variability, conversion of DE to dabigatran via carboxylesterases, and potential saturation of P-gp in the gut at the therapeutic dose may impact its sensitivity and selectivity. 79 Given their relatively low bioavailability ( Table 2) , DE and fexofenadine may be more appropriate P-gp probes in comparison to digoxin when evaluating intestinal P-gp inhibition.
• Endogenous substrates (potential biomarker)
To date, no endogenous probe for P-gp has been identified. 10 Breast cancer resistance protein
• Probe drugs
It is challenging to identify clinical BCRP probes due to the multiplicity of substrates and inhibitors, as well as potential BCRP interactions both in the gut and liver. Following a comprehensive review of in vitro, clinical DDI, and pharmacogenomic data, sulfasalazine has been proposed as an in vivo probe for evaluating intestinal BCRP inhibition, intravenous rosuvastatin for evaluating hepatic BCRP inhibition, and oral rosuvastatin for both intestinal and hepatic BCRP inhibition. 24 Sulfasalazine has limited intestinal absorption due to its low permeability, low solubility, and BCRP-mediated intestinal efflux (Figure 1 , Table 2 ). Plasma AUC of sulfasalazine in wild-type mice increased by 8-fold, following oral dosing of curcumin, a potent BCRP inhibitor, whereas no change was observed in Bcrp −/− mice. 80 In humans, curcumin increased sulfasalazine AUC by 1.8-fold to 3.2-fold 80 ( Table 2 ), suggesting that BCRP plays a significant role in determining the intestinal absorption of sulfasalazine. Of note, sulfasalazine is an MRP2 and P-gp substrate as well, which may limit its intestinal absorption but to a much lower extent than BCRP based on the observations from transporter knockout mice. Furthermore, sulfasalazine is also transported by OATP2B1 in the gut, which is most likely saturated at sulfasalazine's therapeutic dose, and therefore, may not have significant impact on its intestinal absorption. 80 As discussed above, rosuvastatin is a substrate for multiple uptake and efflux transporters, including BCRP. A polymorphism in ABCG2 (c.421C>A) results in a significant increase of rosuvastatin plasma AUC 15, 16 (Table S2) , supporting its use as a BCRP probe. As inhibition of BCRP may alter both the intestinal absorption and hepatobiliary excretion of rosuvastatin, it can be a useful probe to assess inhibitory effects on both gut and hepatic BCRP. 24 Differentiation between the contribution of intestinal and hepatic BCRP is possible only if the appropriate study design is used when rosuvastatin is used as a BCRP probe substrate, as discussed in the study design section presented herein.
• Endogenous substrates (potential biomarker)
To date, no endogenous probe for BCRP has been identified. 10 Transporter probe drug cocktails Because many perpetrator drugs inhibit multiple transporters, concurrent administration of a cocktail containing multiple probe drugs at therapeutic or microdose could be an efficient and valuable tool. The cocktail approach has been successfully applied in drug development and recognized by regulatory agencies to assess DDIs with CYP enzymes. 81 However, the evaluation and use of dedicated drug cocktails to study transporter-related DDIs is still limited. 20, 82, 83 In 2011, Maeda et al. 27 designed a clinical study to identify the rate-determining process in hepatic elimination of atorvastatin using a microdose cocktail of atorvastatin along with probe substrates for OATP1B (pravastatin) and CYP3A (midazolam). Recently, two transporter probe drug cocktails have been proposed for studying DDIs involving transporters and their interplay with CYP3A. A transporter probe cocktail containing a conventional dose of digoxin (0.25 mg, P-gp), rosuvastatin (10 mg, OATP1B and BCRP), furosemide (5 mg, OAT1/3), and metformin (500 mg, OCT2 and MATE1/2K) has been evaluated in vitro 17 and in clinical PK studies. 18, 84 In general, the PK of each probe substrate administered in a cocktail was comparable to when dosed individually, except for a small decrease in peak plasma concentration (C max ) of furosemide and a moderate increase in rosuvastatin C max (38.6%) and AUC (43.4%).
A reduction of the dose of metformin (50 or 10 mg) and furosemide (1 mg) is further recommended to minimize potential interactions between these probes. 84 Recently, in a new trial in which the doses of metformin and furosemide as putative perpetrators were reduced to 10 and 1 mg, respectively, their DDI effects on rosuvastatin were shown to be eliminated. 85 Another microdose cocktail has recently been proposed and validated to study DDIs with OATP1B, P-gp, BCRP, and their interplay with CYP3A. 19 This five-component cocktail contained midazolam (10 μg, CYP3A), DE (375 μg, P-gp), pitavastatin (10 μg, OATP1B), rosuvastatin (25 μg, OATP1B and BCRP), and atorvastatin (50 μg, OATP1B, BCRP, P-gp, and CYP3A). Except for DE, which showed an approximately 2-fold higher magnitude of DDIs with P-gp inhibitors vs. a conventional dose, likely caused by saturation of gut P-gp at DE's conventional dose. PK and the magnitude of DDIs with other microdosed probe drugs were generally comparable to those at their respective conventional doses. Probe drug cocktails allow the simultaneous assessment of DDI risk for different transporters/enzymes and, thus, can provide a mechanistic understanding of complex DDIs involving multiple transporters and enzymes.
MECHANISTIC CONSIDERATIONS AND CHALLENGES OF USING PROBE DRUGS AND ENDOGENOUS BIOMARKERS TO ASSESS TRANSPORTER INHIBITION
This section describes mechanistic considerations and challenges associated with the use of exogenously administered STATE of the ART probe drugs and endogenous biomarkers to study transporter inhibition. Some of the challenges, such as the lack of selectivity toward individual transporters, are common for probe drugs and biomarkers. However, there are also unique challenges. For example, for many endogenous biomarkers, the kinetic determinants of their systemic exposure are poorly understood or defined. These limitations need to be considered when designing clinical studies or extrapolating observed DDIs to new combinations of drugs.
Probe drugs
There are multiple factors that need to be considered prior to qualifying a given drug as a useful "probe" for examining the in vivo activity of a transporter of interest (e.g., absence of additional mechanisms (i.e., selectivity) or the availability of candidate probe drugs in a form that can be safely and ethically administered to humans in a feasible manner; Table 1 ). The paucity of probe drugs possessing sufficient selectivity places a major limitation on the ability to demonstrate the importance of a given transporter ( Table 2 ). As highlighted, in certain instances, testing candidate probe substrates and inhibitors in preclinical species may provide valuable information to guide future clinical investigations. Ultimately, the validation of such probes requires multiple rounds of investigation to identify the appropriate study design and the relatively specific substrate/inhibitor sets that can be utilized clinically.
Overlapping substrate specificities of multiple transporters and metabolic enzymes
Because most transporter probes are substrates of multiple transporters and/or enzymes, there are substantial challenges in selecting a specific probe. As discussed earlier, rosuvastatin is a substrate of BCRP and several other transporters (e.g., OATP1B1, OATP1B3, OATP2B1, NTCP, and OAT3). If a perpetrator drug is also an inhibitor of these transporters, observed DDIs may represent a worst-case scenario for rosuvastatin DDIs, but not inhibition by BCRP alone. In such a case, rosuvastatin clinical DDIs need to be interpreted in conjunction with in vitro and other clinical DDI studies with single or multiple transporter probes of interest or endogenous biomarkers. One promising approach to address the overlapping selectivity of transporters and enzymes, and to maximize clinical study design is to use a transporter and enzyme probe drug cocktail, as discussed in the previous section.
In vivo quantitation of transporter activities
Probe drugs may be used to quantitatively evaluate the effect of an NME on transporter activity in various organs. However, the nature of the biological matrices that can be easily collected (e.g., blood, urine, feces, and saliva) often imposes a major limitation on the practical use of probe drugs in such clinical investigations. The use of stable-labeled or radioisotope-labeled microtracers administered intravenously offers the opportunity to evaluate the effect of the perpetrator drugs on the bioavailability and total body clearance of probe drugs. However, limited ability to assess drug concentration-time profiles in tissues imposes limitations on understanding some of transporter DDIs where changes in systemic exposure do not necessarily reflect events at the tissue level. 24, 68, 86 In such situations, measurement of the tissue concentration-time profiles by noninvasive approaches, such as positron emission tomography, is important for quantifying transporter activities. 87 The integrated efforts of combining in vitro, imaging, and modeling approaches can improve our predictability of tissue concentrations and DDIs. 88, 89 
Other challenges and considerations
Taking into consideration the substrate-dependent inhibition in vitro, 6 translation of clinical DDI data obtained using one probe to other substrate drugs remains uncertain. In vitro studies may be able to bridge the gap assuming the substrate dependence is relevant in vivo. In addition, translation of the data from healthy subjects to specific populations, such as the subjects with hepatic or renal impairment, also remains challenging due to limited information on the change of transporter activity in these populations. 90, 91 
Endogenous biomarkers
Mechanistic understanding of the formation, disposition, and elimination of biomarkers One of the major challenges in translating response of endogenous biomarkers to the inhibition of drug transporters is the poor understanding of the mechanisms involved in their formation, disposition, and/or elimination. Using OATP1B biomarkers as an example, Figure 2 summarizes key elements that need to be considered when interpreting biomarker data. Factors potentially impacting the interpretation of renal transporter biomarker data are shown in Figure S1 . They can be broadly categorized into distinct elements, as described below: selectivity, specificity, sensitivity, and intrinsic or dietary factors. Current knowledge on some emerging biomarker candidates is summarized in Table 3 , but a considerable amount of relevant information is still missing.
Selectivity and specificity of biomarkers for assessing transporter inhibition needs to be carefully considered, as highlighted in the case of probe drugs, but to date there has been limited clinical validation of the specificity and selectivity of potential biomarkers. Sensitivity of the endogenous biomarker is another key determinant of their utility in assessing transporter function, especially if the endogenous biomarker data are to be used to support the lack of an interaction between an NME and a transporter. Additionally, understanding of both intrasubject and intersubject variability of biomarker levels is needed to evaluate the utility of biomarkers in capturing weak or moderate transporter inhibition/DDIs. Some potential endogenous biomarkers, such as bile acids or bilirubin, are associated with either the development of diseases or organ injury; therefore, they are not ideal biomarkers for DDI assessment ( Table 1) . Additionally, some biomarkers may be derived from dietary constituents or metabolites, and, in that case, the potential effects of food should be carefully ruled out. Effect of perpetrator drugs on the biosynthesis of endogenous biomarkers also needs to be considered, as illustrated recently for CPI and creatinine. [92] [93] [94] Genetic polymorphisms of drug transporters can shed light on the mechanistic understanding of endogenous biomarker disposition. One salient example is the altered disposition and elimination of CPI and CPIII due to genetic alterations that affect MRP2 (ABCC2) and OATP1B1 (SLCO1B1) transport activities. 9 In that case, the observed changes in plasma or urine concentrations of these biomarkers may provide quantitative information on the contribution of individual transporters to a given clearance pathway. It is anticipated that the incorporation of such quantitative measures can be particularly useful in verifying physiologically based pharmacokinetic (PBPK) models to describe the PK of endogenous biomarkers.
Kinetic consideration for interpreting biomarker data
One major difference between endogenous biomarkers and probe drugs is that the baseline concentrations of the endogenous biomarkers are determined by the rate of synthesis (as opposed to dose in the case of clinical probe; R in ), along with the rate of degradation/elimination (R out ). When an endogenous biomarker follows first-order elimination, the concentration of the biomarker (C) at any given time can be described as:
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Where CL represents the clearance of the biomarker. Thus, determination of R in and CL values is the key for quantitative, modelbased analysis of biomarker kinetic profiles. When R in and CL are stable over time (i.e., no diurnal fluctuation), the steady-state concentration is described as:
Unlike the probe drugs for which we can control the administered dose, it is challenging to directly estimate R in . This has a significant implication on a model-based analysis of biomarker profile and subsequent quantitative interpretation of DDI observations. One strategy is to utilize isotope tracers of (1) dC dt = R in − CL * C.
(2)
C ss = R in CL . Figure 4 Workflow for the identification, characterization, and validation of transporter endogenous biomarkers. a Recombinant system may be a cellular or a vesicular system that expresses high levels of the transporter of interest. Transport in the overexpressing system is compared with one in a control system with non/low transporter function. b One of the two data types should be a mammalian in vivo model with genetically reduced transport function. c Testing of multiple inhibitors or doses is recommended to provide a range of inhibition potency. If a selective inhibitor is not available, multiple inhibitors with differential overlapping selectivity may be needed. d Possible regulatory review process. For example, US Food and Drug Administration guidance for drug development tools. 100 DDI, drug-drug interaction; GWAS, genomewide association study; KO, knock-out; NHP, nonhuman primate; PGX, pharmacogenetic; PK, pharmacokinetics.
an endogenous biomarker 95 to determine steady-state concentration and CL of a biomarker, and then infer R in based on Eq. 2.
To obtain CL, kinetic profiles after i.v. administration of the biomarker are most informative. Another approach is to administer an isotopic precursor to determine synthesis rate. Alternatively, clinical data for an endogenous biomarker in the presence and absence of a transporter inhibitor can be modeled simultaneously to estimate the rate of biomarker synthesis and elimination clearance, assuming that the inhibitor only affects transportermediated CL, with no effect on R in . 92 Currently, such information is limited to only a few transporter biomarkers 96 and more research is needed to fill the gap to better characterize the kinetic behaviors of biomarkers. Selection of descriptive PK parameters for biomarkers requires careful considerations. The simplest case is a direct evaluation of the changes in pathway-specific clearance (e.g., CL r ) when examining effects on renal transporters. The amount of biomarker excreted into urine over a particular time (A e ) can be expressed as follows:
Therefore, measurement of biomarker AUC and A e in a given time interval allows direct calculation of the effect of test drugs on renal clearance of the biomarker.
The systemic level of a biomarker could be used for the evaluation of transporter function in situations in which the direct measurement is not possible (e.g., modulation in biliary excretion). In such cases, the time course of the biomarker after administration of a perpetrator drug is critical to allow correct interpretation of the DDI data. This time course will be influenced by the terminal half-life (t 1/2 ) of not only the biomarker (which may be synthesis or elimination rate-limited), but also the PK of the transporter inhibitor (or the perpetrator drug). For example, if an inhibitor has a long t 1/2 , its effect on the transporter will be sustained after it reaches its maximum concentration, and the biomarker concentrations will approach new steady-state in accordance with the t 1/2 of the perpetrator drug. In this situation, AUC would be an appropriate metric to interpret changes in transporter function. Figures 3, S2 and Supplementary Materials S1 show various simulations under different scenarios to illustrate these points, and the recommendations on the interpretation of systemic exposure of biomarkers.
Other considerations
Similar to the clinical probe drugs, there is a potential substratedependency in the in vitro half maximal inhibitory concentration or K i values with either different biomarkers and/or biomarkers to substrate drugs. Therefore, translation of DDI data using one biomarker to predict DDI risk with NMEs needs to be fully evaluated assuming the relevance of substrate-dependent phenomenon in vivo. The importance of investigating more than one biomarker is also applicable to the evaluation of inhibitory effect on other transporters. Fully validated bioanalytical methods for reliable and reproducible measurements of biomarkers are critical ( Table 1) .
IDENTIFICATION AND VALIDATION OF ENDOGENOUS BIOMARKERS FOR TRANSPORTER DDI EVALUATION
The identification of novel, sensitive endogenous biomarkers to assess transporter inhibition in a clinical setting follows a series of sequential steps. Initially, a candidate biomarker can be identified from a broad scope of potential data sources and subsequently narrowed down through steps of hit identification, lead characterization, and eventually clinical validation, as detailed in the workflow in Figure 4 .
In vitro and metabolomics approaches
The process of identification may include a combination of in vitro and in vivo approaches to select a candidate endogenous molecule. For example, metabolomic approaches combined with in vitro assays can be used to examine the uptake of endogenous molecules into cells individually expressing transporters of interest following incubation with biological matrices. The utility of these candidate molecules can then be further challenged in systems of increasing complexity, such as knockout rodent models, nonhuman primates, and humans following the administration of a potent and relatively selective transport inhibitor. Finally, the candidate biomarker may be examined in larger populations to verify that variability in its plasma concentrations correlate with known genetic polymorphisms affecting the activity of the transporter of interest. However, there are only a few transporters with clinically meaningful genetic polymorphisms, which may limit this approach. 15, 16 Table S3 provides details and examples on each experimental system. Each system will generate matching test and control samples that will be quantified using metabolomics and enable inferential comparison of dozens of endogenous and exogenous metabolites in parallel and generate candidates. The selected molecules should exhibit robust and consistent responses in all available test systems before they can be considered as biomarkers for the transporter being investigated.
Clinical studies to characterize and validate novel endogenous biomarkers to study transporter inhibition
The identification of an endogenous biomarker in a clinical setting is aimed at investigating the sensitivity, selectivity, and specificity of candidates identified using the steps outlined above. Factors affecting the baseline concentration of a candidate biomarker, such as diet, age, exercise, diurnal variation, and disease state may all confound the ability to observe meaningful changes in the biomarker level upon inhibition of an implicated transporter. Similarly, the participation of additional unidentified transporters in the systemic clearance of the candidate biomarker may also pose an additional challenge. Finally, an understanding of the synthetic and catabolic pathways of the candidate biomarker is necessary to ensure that the test inhibitor does not acutely nor chronically interfere with either pathway. Mechanistic models that combine rates of synthesis, degradation, and transport can be developed, as described in previous sections, to further verify the practicality of the candidate biomarker and perform power calculations to guide the design of clinical DDI studies, as illustrated recently for CPI. 92 
(3)
A e = CL r * AUC.
STATE of the ART Figure 5 Examples of current (a) and future (b) considerations regarding the potential utility of endogenous biomarkers (prevalidated (a) and validated (b)) and probe drugs to assess transporter-related inhibition in drug development. a For transporters without identified biomarkers (e.g., gut transporters), consider to conduct clinical drug-drug interaction (DDI) studies with single or cocktail drug probe(s) at clinically relevant perpetrator dose. b If drugs can potentially inhibit multiple transporters, consider design a drug probe cocktail studies using in vitro and clinically validated probes. If no significant DDIs are observed, dedicated clinical DDI studies with single drug probe at conventional doses may not be needed. If significant DDIs are observed with selected transporters, dedicated clinical DDI studies with drug probes at clinically relevant exposure (both perpetrator and probes) are needed.
Further validation of a candidate biomarker can be done by examining the effect of specific transport inhibitors on the biomarker exposure, preferably in a well-controlled crossover study in subjects who have consented to genomic analysis of the suspected transporter that is known to be polymorphic. Inclusion of a validated probe drug in the study is recommended to enable parallel examination of observed effects. The number of individuals participating in a given trial and the length of treatment should be determined following the appropriate statistical and kinetic analysis of the candidate biomarker PK and extent of contribution of the implicated transporter to the overall systemic clearance. Moreover, confirmatory studies should utilize optimized analytical methods and procedures capable of detecting low levels of the biomarker in the relevant biological matrix. Study design considerations are described in detail in the next section. The results of the clinical study should be used to compare the magnitude of changes in biomarker exposure relative to the changes measured for the transporter probe drug for each of the tested inhibitors.
CLINICAL DDI STUDY DESIGN FOR EVALUATION OF TRANSPORTER INHIBITION WITH CLINICAL PROBE DRUGS OR ENDOGENOUS BIOMARKERS Probe drugs
Due to the complexity of transporter-mediated drug disposition and DDIs, a rational clinical DDI study design is critical to establish whether an NME can act as an in vivo inhibitor of drug transporter(s). Regulatory DDI guidance documents have provided some recommendations on the design of clinical DDI studies, which, in general, can be applied to transporter DDIs. [12] [13] [14] Additional practical considerations for designing clinical DDI studies using the probe drugs or cocktails highlighted in the previous section are discussed below.
Subjects
Transporter DDI studies are generally conducted in healthy subjects, rather than patients, unless there are safety concerns. Extrapolation of DDI results from healthy subjects to a specific and/or diseased population requires prior knowledge on alternation of transporter expression and/or activity in addition to the changes of relevant physiological parameters. Limited knowledge is currently available in this emerging area to allow direct translation of clinical DDIs to these specific populations. 90, 91 Carriers of certain genetic polymorphisms (e.g., SLCO1B1 c.521T>C and ABCG2 c.421C>A) will have a diminished response to transport inhibitors as previously described. 15, 16, 24, 97 In the context of this article, these variants are specifically relevant for pitavastatin for OATP1B1 (SLCO1B1) and rosuvastatin for BCRP (ABCG2). Thus, it is recommended to genotype subjects for SLCO1B1 and ABCG2 prior to enrollment or at least collect such information after the trial to help data analysis and interpretation 15 (e.g., in case outliers are identified). Currently, genetic information may not be available in cocktail DDI studies that are conducted as a nested arm in a large clinical trial (e.g., secondary DDI endpoint in a phase I trial). However, if the DDI under investigation involves OATP1B1 and/or BCRP inhibition, the inclusion of the genetic analysis in study protocols would be helpful to interpret DDI results.
Dose and dose regimen
In general, the doses of probe and perpetrator drugs should be clinically relevant to appropriately characterize the DDIs. Based on this consideration, the maximum approved dose and shortest dosing interval should be used for transporter inhibitors. For probe drugs, potential saturation of drug transporters at a given dose (e.g., intestinal P-gp) needs to be considered, as it may reduce the sensitivity of the measurements. Cocktail probes (at either microdose or therapeutic dose) need to be validated with both PK and clinical DDI studies to confirm the translation of the data to clinical DDIs and the lack of interaction between different probes. In some cases, the magnitude of DDIs at microdose level can be higher than those observed at the therapeutic dose due to the saturation of transporters at therapeutic doses (especially relevant in the intestine). 19 In such cases, microdose data could be considered a worst-case scenario for transporter DDIs and observed DDIs may not be directly translated to therapeutic dose for dosing adjustment. 19 NMEs with complex inhibition/induction liabilities may require single-dose assessment of the inhibitory effects, and combined induction/inhibition effects following chronic administration (e.g., rifampin, an inhibitor of OATP1B and inducer of CYP3A/P-gp 98 ).
As with all DDI studies, the sequence of administration and the time interval between dosing of the probe drug and perpetrator can impact the outcome. For example, when using the prodrug DE as an in vivo probe for intestinal P-gp, oral dosing of the P-gp inhibitor should precede DE administration to ensure maximum exposure considering rapid hydrolysis of DE to the non-P-gp substrate dabigatran. 99 In most cases, both perpetrator and probe drugs are orally administered, which may reflect the clinical setting. However, use of both i.v. and oral dosing of probe drugs or perpetrators may provide additional mechanistic insight into the relative contributions of intestinal vs. hepatic transporters to the observed DDIs. For example, oral rosuvastatin is recommended to evaluate the DDIs resulting from the inhibition of both intestinal and hepatic BCRP, whereas i.v. rosuvastatin can be used to evaluate the contribution of hepatic BCRP. 24 Because rosuvastatin is also a substrate for hepatic OATP1B, possible effect on OATP1B, for perpetrator drugs that may affect both OATP1B and BCRP, need to be considered for data interpretation or minimized (e.g., by enrolling subjects with SLCO1B1 c.521C/C genotype). In addition, monitoring the cholesterol-lowering effect of rosuvastatin is suggested for assessing the perpetrator effect on hepatic BCRP. Similarly, i.v. and oral rifampin have been used as a perpetrator to understand the selectivity of pitavastatin (OATP1B) and rosuvastatin (BCRP/OATP1B) as DDI probe drugs for hepatic and intestinal transport activity, respectively. 22 
Study endpoints
Changes in systemic exposure of probe drugs (AUC and C max ratio with and without inhibitor) are generally used to describe the extent of transporter DDIs. Besides these parameters, CL r of STATE of the ART probe drugs should also be measured over the PK sampling period when studying renal transporter DDIs. In such cases, urinary pH should also be measured to understand potential variability of reabsorption for probes with Pka values within urinary pH range. PD endpoints are generally not included in DDI studies. However, metformin may represent an example that, including PD endpoints, could help to interpret clinical DDI data and enable rational dose adjustment. 42, 43 
Endogenous biomarkers
The design of a clinical study to explore changes in the level of a validated endogenous biomarker after administration of an NME will benefit from a clear understanding of biomarker clearance(s). Characterization of such kinetic parameters may require monitoring of the disposition of an endogenous biomarker using radiolabeled or stable isotopes. The availability of quantitative data on disposition mechanisms (e.g., metabolic and renal clearance, in vitro transporter kinetics) and rates of synthesis allows the subsequent development of biomarker PBPK models. Such models can be used to simulate the changes in exposure due to the inhibition of transporter(s) and aid in the design of clinical investigations aimed at maximizing the sensitivity of a given biomarker. In all cases, a crossover study design is preferred given the expected variability in the exposure, rate of elimination, and rate of synthesis in humans. The study design should take into consideration the appropriate time frame to collect the matched-samples based on PBPK simulations conducted in the absence or presence of the test inhibitor.
The use of a standard cutoff value for the change in biomarker exposure may not be possible with all candidate transporters due to variability in the magnitude of interactions. Instead, a systematic increase in the exposure of the biomarker that corresponds to an increase in the dose of the test inhibitor is recommended as a positive indication of an interaction with the transporter of interest. Ideally, bioanalysis of the biomarker concentration in the biological matrices (e.g., plasma, urine, and saliva) can be added onto typical first-in-human investigations aimed at verifying the safety and tolerability of NME that have been identified as transport inhibitors in vitro or in preclinical species. Such studies will provide a comprehensive dataset to verify the dose-dependent changes in the exposure of the biomarker for the transporter of interest up to supratherapeutic dose levels.
Altered transport activity due to genetic polymorphisms may complicate the ability to detect exposure changes of a drug probe and can affect biomarker concentrations at baseline. Therefore, understanding of this covariate on the systemic exposure of the biomarker and associated variability is important. Moreover, the extent of change above baseline during the course of treatment is likely to be lower in subjects with a reduced function allele than in wild-type subjects. Prior knowledge on the genetic makeup of subjects participating in the trial would be beneficial for biomarkers of transporters with clinically relevant polymorphism (e.g., SLCO1B1, ABCG2, and SLC22A1 (OCT1)) to explain interindividual variability.
To address multiple sources of interindividual variability in biomarker baseline concentrations, a crossover study design in a sufficiently large number of test subjects (based on power calculations) is required to demonstrate statistical significance. Ideally, the biomarker concentration would be monitored at the beginning of the study period and again after 5-7 days to allow for subject acclimation under the clinical trial conditions. Moreover, synchronization of study procedures ensures that potential diurnal fluctuations in the biomarker level in individuals are not drastically affected in the subjects undergoing the study. Subjects would subsequently receive the test inhibitor preferably following an 8-10-hour fast until steady-state exposure is reached. Test inhibitor should be administered in a consistent manner to all test subjects (e.g., oral administration followed by the consumption of 250 mL of water) and subjects would consume the meals in a standardized fashion to rule out any potential food effect on biomarker and inhibitor PK. In each period of the study, blood samples (or other matrices) will be collected postdose, the number of samples and time of collection should closely match the PK of the test inhibitor to ensure capturing changes in the biomarker level when the inhibitor is at C max and trough plasma concentration C trough levels. Additional treatment cycles in which the dose of the inhibitor is escalated should be done in a consistent manner and additional sets of blood samples are collected at steady-state levels. Changes in the biomarker exposure that match the inhibitor dose would be assessed. Ideally, changes in the biomarker exposure in individual subjects should correlate with the inhibitor dose as an indication that the examined biomarker is suitable to address the inhibition of the transport activity.
RECOMMENDATION AND PERSPECTIVES OF APPLYING PROBE DRUGS AND ENDOGENOUS BIOMARKERS TO STUDY TRANSPORTER INHIBITION
The utility of probe drugs and endogenous biomarkers to assess inhibition potential of NMEs on drug transporters are summarized in Figure 5 . Monitoring plasma and/or urine exposure of endogenous biomarkers for various transporters could be incorporated in early human PK studies, such as phase I dose escalation studies. Most of the biomarkers reported thus far are not fully validated for their sensitivity, selectivity, and specificity. Therefore, at present time (Figure 5a ), in vivo biomarker data can only be used for designing DDI assessment strategy or for prioritizing the clinical DDI studies with probe substrate drugs (as individual or in a cocktail) or with the most relevant concomitant medications. The data need to be interpreted with the understanding that positive data may imply a potential DDI, but may not be specific for a particular transporter and may potentially be confounded by inhibition on the synthesis of the biomarker. Furthermore, lack of interaction between the NME and the biomarker does not ensure one did not occur and additional targeted evaluation of particular DDIs of concern using probe substrate drugs would be warranted.
Once selectivity and sensitivity of an endogenous biomarker have been validated (Figure 5b) in humans, it can be used for early assessment of transporter-based DDIs in single and multiple ascending dose phase I studies. We envisage that the use of a sensitive and selective biomarker would potentially obviate the need to administer a probe substrate drug in a dedicated DDI study, avoiding unnecessary drug exposure to participants and to reduce cost. The in vivo biomarker data would also be useful to develop and optimize mechanistic PBPK models for predicting unstudied scenarios for dosing recommendation or for informing additional clinical studies. In vivo biomarker data together with clinical DDI results obtained from individual and/or cocktail probe drugs and PBPK modeling can also provide a mechanistic insight to predict complex DDIs involving inhibition of multiple transporters and enzymes. Such an integrated approach will ensure understanding of the full dose response with respect to transporter inhibition/induction liability of an NME as a perpetrator, while minimizing DDI studies conducted in response to false-positive predictions using in vitro data. It is worth noting that continuing efforts to identify and validate new and existing biomarkers are critically needed. Another targeted effort is to identify probe substrate drugs that are suitable for cassette DDI assessment and exhibit high sensitivity to evaluate transporter inhibition, but with minimal potential for mutual interactions between the components of the cocktail. Precompetitive efforts and dedicated consortia may be valuable in coordinating targeted efforts and accelerating the incorporation of biomarkers and probe drug cocktails in drug development.
In summary, multiple endogenous molecules whose exposure is modulated due to interactions with drug transporters have been identified to support the clinical development of safe and effective therapeutics. Ideally, suitable biomarkers would enable gauging the risk of interactions with clinically relevant transporters. In reality, examples of promising candidate biomarkers are currently only being identified and studied for interactions with several hepatic (OATP1B) and renal transporters (OCT2/MATE1/2K and OAT1/3), but there is a considerable increase in published information. There has been a clear absence of candidate biomarkers to examine P-gp and BCRP inhibition, which is likely due to lack or limited involvement of gut P-gp and BCRP on in vivo disposition of endogenous substrates, and the difficulty associated with estimating the extent of individual contribution of gut, hepatic, and renal P-gp and BCRP to the systemic clearance of biomarkers. Continued measurement of candidate biomarkers in clinical studies in which transporter interactions are anticipated needs to become more widespread. This is only possible if suitable language is included in early clinical study protocols to ensure adequate consent from the human subjects. This will ultimately enhance the confidence in the suitability of measuring changes in biomarker concentrations as an indicator of potential clinical transporter DDIs from pharmaceutical and regulatory perspectives.
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